| Indication | Immunology and inflammation |
| Drug | Skyrizi |
| Company | AbbVie |
| Category | Corporate & Strategic |
| Sub Category | Acquisition Announced |
| Therapeutic Area | Immunology |
| Q2 Net Revenue | $16.99 billion |
| I&I Portfolio Revenue | $8.79 billion |
| Skyrizi Revenue | $5.5 billion |
| Neuroscience Unit Revenue | $3.23 billion |
| Share Decline | 4% |
| EPS Guidance Range | $13.87 to $14.07 |
| Apogee Acquisition Value | $10.9 billion |
| PDUFA Date | December 31 |
| Parkinson's Market Potential | $5 billion |
| Regulatory Agency | FDA |
AbbVie's Q2 I&I Beat Fails to Meet High Investor Expectations
AbbVie's shares experienced a nearly 4% decline to $247.50 following its Q2 earnings report, despite the company's immunology and inflammation (I&I) portfolio exceeding consensus expectations. The market reaction was attributed to investor expectations for a more substantial beat. The I&I portfolio generated $8.79 billion in revenue, marking a 15% increase year-over-year, with Skyrizi contributing $5.5 billion and Rinvoq $2.53 billion. Additionally, AbbVie updated its earnings per share (EPS) guidance to a range of $13.87 to $14.07, noting that a four-cent reduction was due to the recently announced acquisition of Apogee Therapeutics. The company's neurology programs also performed well, and a regulatory decision for tavapadon in Parkinson's disease is anticipated by year-end.
- Despite AbbVie's immunology and inflammation (I&I) portfolio surpassing consensus expectations, the magnitude of this beat was perceived as insufficient by investors, leading to a nearly 4% drop in the company's share price to $247.50. Analysts from BMO Capital Markets highlighted that while the results were positive, they did not meet the high expectations typically associated with AbbVie's performance, thus contributing to the market pressure.
- AbbVie's I&I portfolio demonstrated strong financial performance, achieving a total revenue of $8.79 billion for the second quarter, representing a 15% increase compared to the same period last year. Within this portfolio, Skyrizi, identified as the company's 'new immunology standard-bearer,' generated $5.5 billion, while Rinvoq contributed $2.53 billion, both exceeding their respective consensus estimates.
- In contrast to the I&I portfolio's market reception, AbbVie's neurology programs garnered positive attention from analysts, reporting a 4% beat with $3.23 billion in revenue. This performance was driven by therapies such as Vraylar and the better-than-expected launch of Vyalev for Parkinson's disease, which brought in $256 million. The company also highlighted tavapadon, an oral drug for Parkinson's, for which a regulatory decision from the FDA is expected by December 31, potentially adding $5 billion to the market in this disease area.
- AbbVie's strategic initiatives include the recent $10.9 billion acquisition of Apogee Therapeutics, aimed at strengthening its I&I pipeline. CEO Robert Michael emphasized the company's robust financial capacity, signaling a continued focus on pursuing additional business development opportunities, both early and late-stage, across its core therapeutic areas to fuel future growth and innovation.
Apogee Acquisition: Targeting Emerging I&I Mechanisms to Rival Dupixent
Recent research in immunology and inflammation is revealing a diverse array of therapeutic targets beyond established pathways. These emerging mechanisms offer the potential for more precise immunomodulation, aiming to improve efficacy and overcome treatment resistance in a range of inflammatory and autoimmune disorders.
Post-Translational Modifications (PTMs) of NF-κB: Therapeutic strategies are shifting towards targeting the PTMs of NF-κB, such as phosphorylation, acetylation, and ubiquitination. This approach allows for fine-tuning NF-κB activation, nuclear translocation, and transcriptional specificity, which can reprogram the immune landscape and counteract immunotherapy resistance driven by NF-κB's influence on PD-L1 and IDO1 expression.
Pyruvate Kinase M2 (PKM2) Modulation: PKM2, a metabolic enzyme with protein kinase function, is being explored as a therapeutic target at the intersection of metabolism and inflammation. Its role in cancer and inflammatory diseases is determined by its conformational state, PTMs, and subcellular localization, with preclinical studies exploring various compounds that modulate its activity and expression.
CXCR1/2 Receptor Antagonism: The chemokine receptors CXCR1 and CXCR2, which mediate immune cell migration and inflammatory mediator release, represent a key target. Novel antagonists such as SCH527123 inhibit CXCL8/IL-8 binding, demonstrating preclinical anti-inflammatory and anti-tumor activity in models of cancer, COPD, and asthma.
The β-TRCP1/RSK3/OTUD3 Pathway: A recently identified signaling axis has been shown to regulate cGAS-driven innate immune responses. The E3 ubiquitin ligase β-TRCP1 targets the deubiquitinase OTUD3 for degradation, providing a fine-tuning mechanism for innate immunity that presents a potential therapeutic target for autoimmune diseases and cancer.
The PAD/Citrullination Axis: The peptidylarginine deiminase (PAD)/citrullination axis is a driver of autoantigen generation in several immune-mediated diseases. Emerging strategies extend beyond direct PAD inhibition to include a "substrate-centric" intervention, which aims to shield key arginine residues on autoantigens to prevent the formation of immunogenic neoepitopes.
TYK2 Allosteric Inhibition: Tyrosine kinase 2 (TYK2) is a critical node in the JAK-STAT pathway that integrates signals from type I interferons, IL-12, and IL-23. Selective allosteric inhibitors, such as deucravacitinib, offer a highly specific method for modulating TYK2 signaling, with demonstrated clinical efficacy in psoriasis and other immune-mediated disorders.
Cathepsin C (CatC) Inhibition: CatC, a lysosomal dipeptidyl peptidase, is being targeted for its role in processing and activating pro-inflammatory precursors like neutrophil serine proteases and granzymes. Inhibiting CatC is being explored as a way to disrupt inflammatory cascades and modulate immune responses in a variety of immunological diseases.
Frequently Asked Questions
References
- [1] Kang R, Sun A et al.. Targeting the plasticity of intestinal neutrophils: bidirectional regulation strategies by natural products. Frontiers in immunology. 2025. 41601690
- [2] Tamimi R, Tafazzoli-Shadpour M et al.. Determinants of MSC immunophenotypic plasticity: From canonical priming to emerging strategies for cancer and inflammatory therapies. Biochimica et biophysica acta. Reviews on cancer. 2026 Sep. 42264158
- [3] Toh CH, Bates I et al.. Medical haematology: Repositioning haematology at the centre of medicine. British journal of haematology. 2026 Mar. 41556724
- [4] Funk GA, Xie J et al.. Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory Therapy. ACS pharmacology & translational science. 2026 Jan 9. 41536275
- [5] Awais M, Baroudi M et al.. Therapeutic Immunomodulation in Cardiovascular Disease: Anti-inflammatory Strategies and Landmark Trials. Cureus. 2025 Dec. 41573444
- [6] Mohaghegh N, Balajam NZ et al.. Immunoengineering strategies using nanoparticles for obesity treatment. Nano research. 2025 Dec. 41602577
- [7] Sutradhar SC, Banik N et al.. Polymer Network-Based Nanogels and Microgels: Design, Classification, Synthesis, and Applications in Drug Delivery. Gels (Basel, Switzerland). 2025 Sep 22. 41002535
- [8] Wang L, Wu H et al.. Single-cell RNA sequencing reveals neutrophil differentiation-related genes for immunotherapy response prediction in colorectal cancer. BMC cancer. 2025 Nov 22. 41275131
- [9] Ma B, Bai G et al.. Antigen-specific IgY as an orally deliverable biomaterial for sustained immunomodulation in ulcerative colitis. Colloids and surfaces. B, Biointerfaces. 2026 May 13. 42140132
- [10] Aljabali AAA, Obeid MA et al.. Cathepsin C: a critical mediator between immune response and cardiovascular disease - therapeutic implications of enzyme inhibition. Drug development and industrial pharmacy. 2025 Oct 14. 41065194
- [11] Huang L, Xu R et al.. Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation. Frontiers in cardiovascular medicine. 2026. 42291533
- [12] Amalo RB, Budiawan H et al.. Visualizing the metabolic battleground: the role of PET imaging in understanding immunometabolism and the tumor microenvironment. Nuclear medicine communications. 2026 Aug 1. 41913679
- [13] Goemaere I, De Velder M et al.. Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies. Advanced drug delivery reviews. 2026 Sep. 42349554
- [14] Zhong JM, He JW et al.. Potential of CXCR1/2 as a target for the treatment of inflammation and cancer (Review). Experimental and therapeutic medicine. 2025 Dec. 41089196
- [15] Chen Q, Ma Y et al.. Beyond PAD Inhibition: Emerging Avenues and Natural Products for Targeting Citrullination in Immune Diseases. Biomedicines. 2026 Apr 8. 42072391
- [16] Wang J, Zhang W et al.. Targeting Pyruvate Kinase M2: Signal Transduction Pathways and Exploration of Cancer Therapeutic Strategies. The AAPS journal. 2026 Jun 2. 42230450
- [17] Liu Y, Li J et al.. Bioinspired nanomicelles with octopus-like adhesion for microenvironmental reprogramming in periodontitis. Journal of controlled release : official journal of the Controlled Release Society. 2026 Apr 10. 41570864
- [18] Chen J, Sivashankar S et al.. The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation. The Journal of biological chemistry. 2026 Jun. 41999888
- [19] Wei M, Gao C et al.. Polysaccharide-based anticancer therapeutics: molecular mechanisms, translational advances, and the road toward precision oncology. Frontiers in pharmacology. 2026. 42088587
- [20] Sharma A, Kumar I et al.. TYK2 signaling as a molecular bridge between cytokine storm and chronic inflammation: therapeutic implications of deucravacitinib. Molecular biology reports. 2026 Jul 3. 42397595
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
